Valuable insights from real-life experiences of advanced thyroid cancer treatment with sorafenib in Latin America

Arch Endocrinol Metab. 2021 Sep 2;65(4):401-403. doi: 10.20945/2359-3997000000398.

Authors

Evelin C Farias¹, Ana Oliveira Hoff²

Affiliations

¹ Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, SP, Brasil, evelin_cf@hotmail.com.
² Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, SP, Brasil, ana.hoff@hc.fm.usp.br.

No abstract available

Publication types

Editorial

MeSH terms

Antineoplastic Agents* / therapeutic use
Humans
Latin America
Niacinamide / therapeutic use
Phenylurea Compounds / therapeutic use
Sorafenib / therapeutic use
Thyroid Neoplasms* / drug therapy

Substances

Antineoplastic Agents
Phenylurea Compounds
Niacinamide
Sorafenib